Europium chloride, anhydrous 99.9% → Thyroxine

HRID 257615

反应方程式

HRID 257615 反应方程式
[Cl-].[Eu+3].[Cl-].[Cl-].[Na+].[NH2:6][C@H:7]([C:27]([O-:29])=[O:28])[CH2:8][C:9]1[CH:16]=[C:14]([I:15])[C:13]([O:17][C:18]2[CH:25]=[C:23]([I:24])[C:22]([OH:26])=[C:20]([I:21])[CH:19]=2)=[C:11]([I:12])[CH:10]=1>CN(C)C=O.C(O)C>[NH2:6][C@H:7]([C:27]([OH:29])=[O:28])[CH2:8][C:9]1[CH:10]=[C:11]([I:12])[C:13]([O:17][C:18]2[CH:19]=[C:20]([I:21])[C:22]([OH:26])=[C:23]([I:24])[CH:25]=2)=[C:14]([I:15])[CH:16]=1

参与物

5

反应物 2

HCID 9859933Europium chloride, anhydrous 99.9%HCID 23666112Levothyroxine Sodium2 次

产物 1

HCID 5819Thyroxine

试剂、催化剂与溶剂 2

HCID 702乙醇溶剂2 次HCID 6228N,N-二甲基甲酰胺溶剂

实验过程

Fluorescent compound (v) synthesized in Example 4 was dissolved in dimethylformamide at a concentration of 5.0×10-5M, and thyroxine sodium salt was dissolved in ethanol at a concentration of 5.0×10-5M. The fluorescent compound (v) solution (100 μl) and the thyroxine sodium salt solution (100 μl) of ethanol were mixed and incubated for 30 minutes at room temperature with stirring. The resulting solution was subjected to a HPLC purification (column: AP-313, YMC Co., solvent: methanol: water=3:7(v:v) including 0.02% acetic acid) and the fluorescent compound (v)-labelled thyroxine was purified. The fluorescent compound (v)-labelled thyroxine was identified by measuring the thyroxine activity using an enzyme immunoassay (Boehringer Mannheim GmbH), and by measuring fluorescence intensity of the solution prepared by mixing equal volume of europium chloride (1×10-5M) and the fraction.

后处理

  1. customThe resulting solution was subjected to a HPLC purification (column: AP-313, YMC Co., solvent: methanol: water=3:7(v:v)
  2. customwas purified
  3. customprepared

来源与证据

ORD记录
ord-47de7a514e3547679a0e2c8e966c64ef
来源数据集
uspto-grants-1993_11
专利号
US05262526

关联笔记

加载中…